US biotech firm Viela Bio raises $250m in Temasek-backed Series A

US biotech firm Viela Bio raises $250m in Temasek-backed Series A

Visual from Viela Bio's website

US-headquartered Viela Bio, an inflammation and autoimmune biotech spinout of AstraZeneca, has raised $250 million in Series A funding backed by Singapore state-owned investment firm Temasek.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter